Free/total prostate-specific antigen ratio can prevent unnecessary prostate biopsies

Objectives. To evaluate the ability of free/total prostate-specific antigen (PSA) ratio to improve specificity of prostate cancer detection, compare Diagnostic Products Corporation (DPC) Immulite and Ciba Corning ACS 180 total (t)PSA assay, and define an assay-specific cutoff point and reflex range...

Full description

Saved in:

Bibliographic Details
Published in:	Urology (Ridgewood, N.J.) Vol. 52; no. 3; pp. 479 - 486
Main Authors:	Trinkler, Felix B, Schmid, Daniel M, Hauri, Dieter, Pei, Patric, Maly, Friedrich E, Sulser, Tullio
Format:	Journal Article
Language:	English
Published:	New York, NY Elsevier Inc 01-09-1998 Elsevier Science
Subjects:	Aged Aged, 80 and over Biological and medical sciences Biopsy Decision Trees Humans Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Prospective Studies Prostate - pathology Prostate-Specific Antigen - blood Prostatic Hyperplasia - blood Prostatic Hyperplasia - diagnosis Sensitivity and Specificity Tumors of the urinary system Urinary tract. Prostate gland Human Adenocarcinoma Urinary system disease Prostate disease Exploration Male Histology Tumoral marker Malignant tumor Prostate specific antigen Pathology Biopsy Adult Diagnosis Male genital diseases Prostate
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Objectives. To evaluate the ability of free/total prostate-specific antigen (PSA) ratio to improve specificity of prostate cancer detection, compare Diagnostic Products Corporation (DPC) Immulite and Ciba Corning ACS 180 total (t)PSA assay, and define an assay-specific cutoff point and reflex range for DPC PSA ratio (PSAR). Methods. In a prospective study, 206 men were enrolled with measurement of both assays. Group 1 consisted of 173 men with a suspicion of prostate cancer (PCA). Thirteen men with known PCA (group 2) and 20 men younger than 32 years (group 3) were used as control groups. Results. Our results in group 1 (115 with benign prostatic hyperplasia [BPH], 58 with PCA) revealed a sensitivity of 82.7%, a specificity of 45.2%, and an accuracy of 57.8% for the DPC tPSA assay (cutoff point more than 4.0 ng/mL) within the entire PSA range. tPSA values of the ACS 180 assay were 1.97-fold higher. Within the tPSA gray zone of 2.5 to 10 ng/mL (66 BPH, 23 PCA), specificity and accuracy of DPC tPSA can be improved by using the DPC PSAR (cutoff point less than 19%) from 33.3% to 71.2% and 42.7% to 70.8%, respectively, maintaining the same sensitivity level of 69.6%. Conclusions. By combining tPSA testing with PSAR within the gray zone, 39.7% (25 of 63) of unnecessary biopsies can be saved, without missing any additional cancers compared with tPSA testing alone. The optimal reflex range for DPC PSAR is 2.5 to 10 ng/mL and the best PSAR cutoff point for biopsy criterion is less than 19% in our high-risk population, with a cancer yield of 34%. Because we still do not have an international PSA standard, it is important to use assay-specific “normal values” and PSAR cutoff points.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0090-4295 1527-9995
DOI:	10.1016/S0090-4295(98)00157-5